Double Blind, two dose, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Sponsor: |
NIH - NIMH |
Enrolling: |
Male and Female Patients |
IRB Number: |
7370 |
U.S. Govt. ID: |
NCT02978599 |
Contact: |
James Gangwisch PhD: 646-774-8433 / jeg64@columbia.edu |
AVL-3288 is an experimental medication that effects the nicotine receptors in the brain that isbeing initially developed for the treatment of cognitive problems in patients with schizophreniaaccompanied. To date, no specific treatments for cognitive deficits in schizophrenia exist and approvedtherapies do not satisfactorily improve cognition.
This study is closed
Investigator
Jeffrey Lieberman, MD
Do you suffer from schizophrenia? |
Yes |
No |